NasdaqCM - Nasdaq Real Time Price USD
Cardiff Oncology, Inc. (CRDF)
1.6900 -0.0100 (-0.59%)
At close: April 16 at 4:00:01 PM EDT
1.6901 +0.0001 (+0.01%)
After hours: April 16 at 6:08:05 PM EDT
Trade CRDF on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for CRDF
Chart does not reflect overnight price.
- Previous Close
1.7000 - Open
1.6900 - Bid 1.6500 x 400
- Ask 1.7200 x 400
- Day's Range
1.6500 - 1.7289 - 52 Week Range
1.4800 - 4.5600 - Volume
667,141 - Avg. Volume
1,076,791 - Market Cap (intraday)
115.537M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6900 - Earnings Date (est.) May 7, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.75
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
www.cardiffoncology.comRecent News: CRDF
View More
Performance Overview: CRDF
Trailing total returns as of 4/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CRDF
39.86%
S&P 500 (^GSPC)
2.86%
1-Year Return
CRDF
39.86%
S&P 500 (^GSPC)
33.47%
3-Year Return
CRDF
13.42%
S&P 500 (^GSPC)
70.18%
5-Year Return
CRDF
79.59%
S&P 500 (^GSPC)
68.23%
Earnings Trends: CRDF
View MoreAnalyst Insights: CRDF
View MoreStatistics: CRDF
View MoreValuation Measures
As of 4/15/2026
Market Cap
115.54M
Enterprise Value
58.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
190.49
Price/Book (mrq)
2.55
Enterprise Value/Revenue
97.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.47%
Return on Equity (ttm)
-71.45%
Revenue (ttm)
593k
Net Income Avi to Common (ttm)
-45.88M
Diluted EPS (ttm)
-0.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
58.3M
Total Debt/Equity (mrq)
1.83%
Levered Free Cash Flow (ttm)
-19.62M
Compare To: CRDF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: CRDF
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: CRDF
View MoreDaily – Vickers Top Buyers & Sellers for 08/01/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/23/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/14/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 06/18/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.